Journal Watch · European Heart Journal · 2026

Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.

Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

Aba N, Le Teuff G, Fresneau B et al.European Heart Journal3 min readPharma relevance 50/100

DOI: 10.1093/eurheartj/ehaf617PMID: 40985963Study type: research study

TL;DR

Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

Key findings

  • Incorporating NFE2L2 gene expression into prognostic models improved discrimination between cases and controls compared with models based solely on clinical and treatment variables [CD: area under the curve (AUC) .85 vs .66; HF: AUC .87 vs .77].<h4>Conclusions</h4>Using high-dimensional data selection methods has enabled the identification of the gene NFE2L2, associated with CD and HF in CCS.
  • Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

Numbers at a glance (from the abstract)

95%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

The intersection of the three selected gene sets formed the final selection. The interactions between cancer treatment doses and selected genes were investigated.<h4>Results</h4>One promising gene, NFE2L2, constituted the final selection, and its expression was lower in cases than in controls [CD: odds ratio (OR) .16, 95% confidence interval (CI) .09-.29; HF: OR .11, 95% CI .03-.37]. No interaction between treatment doses and NFE2L2 expression levels was found in our study.

Full abstract (original)

Background: <h4>Background and aims</h4>Cardiotoxic treatments like anthracyclines and heart-directed radiotherapy increase the risk of cardiac diseases (CDs) in childhood cancer survivors (CCSs), but individual differences in CD incidence are not fully understood. This study aims to identify transcriptomic biomarkers associated with CD occurrence after childhood cancer treatment.<h4>Methods</h4>A matched case-control study was conducted on a sample of 330 CCS: 165 cases with CD and 165 CD-free controls. The expression of 8557 genes was investigated to select those associated with CD and heart failure (HF), using three stabilization approaches derived for the conditional logistic regression with Lasso (Percentile lasso, Bolasso, and Sublasso).

What they did: The intersection of the three selected gene sets formed the final selection. The interactions between cancer treatment doses and selected genes were investigated.<h4>Results</h4>One promising gene, NFE2L2, constituted the final selection, and its expression was lower in cases than in controls [CD: odds ratio (OR) .16, 95% confidence interval (CI) .09-.29; HF: OR .11, 95% CI .03-.37]. No interaction between treatment doses and NFE2L2 expression levels was found in our study.

Results & conclusions: Incorporating NFE2L2 gene expression into prognostic models improved discrimination between cases and controls compared with models based solely on clinical and treatment variables [CD: area under the curve (AUC) .85 vs .66; HF: AUC .87 vs .77].<h4>Conclusions</h4>Using high-dimensional data selection methods has enabled the identification of the gene NFE2L2, associated with CD and HF in CCS. Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

Abstract © the authors / European Heart Journal (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1093/eurheartj/ehaf617 · PubMed 40985963.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking European Heart Journal for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this European Heart Journal study find?

Further research is needed to validate this finding and achieve a better understanding of the biological mechanisms leading to cardiac toxicities and so to develop risk-adapted treatment and surveillance strategies.

What type of study is this?

It is a research study, published in European Heart Journal in 2026. The intersection of the three selected gene sets formed the final selection.

Where can I read the original paper?

The original is at the publisher via DOI 10.1093/eurheartj/ehaf617. PubMed ID: 40985963. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Aba N, Le Teuff G, Fresneau B et al.. Transcriptomic biomarkers related to cardiac disease in childhood cancer survivors: a case-control study.. European Heart Journal (2026). DOI: 10.1093/eurheartj/ehaf617.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/transcriptomic-biomarkers-related-to-cardiac-disease-in-childhood-cancer-haf617/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides